Zusammenfassung
Die Indikationen fiir eine immunsuppressive Therapie chronisch ent-ziindlicher Darmerkrankungen sind klar definiert (Stange et al. 1997, 2001). Es sind dies der steroidabhangige sowie der steroidrefraktare Krankheitsverlauf des Morbus Crohn und der Colitis ulcerosa.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Literatur
Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2001) An open-label pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 7:181–189
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705–713
Feagan BG, Fedorak RN, Irvine EJ et al. (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632
Feagan BG, Rochon J, Fedorak RN et al. (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 332:2927
Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, Loeschke K, Stange EF (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176
Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50:485–489
Herrlinger KR, Kreisel W, Schwab M et al. (2002) Open prospective trial an 6-thioguanine for chronic active Crohn’s disease. DDW 2002: Abstract
Lawson SE, Harrison G, Richards S, Oakhill A, Stevens R, Eden OB, Darbyshire PJ (2000) The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report an the medical research council UKALLR1 study. Br J Haematol 108: 531–543
Lemann M, Chamiot-Prieur C, Mesnard B et al. (1996) Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther 10:309–314
Mason C, Knieger GG (2001) Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol 44:67–72
Mathew TH (1998) A blinded, long-term, randomized multicenter study of mycophe-nolate mofetil in cadaveric renal transplantation: results at three years. Triconti-nental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65:1450–1454
Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol 96: 782–787
Murphy FP, Coven TR, Burack LH, Gilleaudeau P, Cardinale I, Auerbach R, Krueger JG (1999) Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects an activated T lymphocytes. Arch Dermatol 135:1495–1502
Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628
Sandborn WJ (1998) Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol 33(Suppl): 225:92–99
Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225–232
Stange EF, Riemann J, von Herbay A et al. (2001) Diagnosis and therapy of ulcerative colitis-results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 39:19–20
Stange EF, Schreiber S, Raedler A et al. (1997) Therapy of Crohn diseases-results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 35: 541–554
Stange EF, Schreiber S, Raedler A, Stallmach A, Scholmerich J, Loeschke K, Starlinger M, Fischbach W, Caspary WF (1997) Therapy of Crohn diseases — results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases. Z. Gastroenterol. 35: 541–554
Steinherz PG, Gaynon PS, Breneman JC et al. (1998) Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children’s Cancer Group. Cancer 82:600–612
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Herrlinger, K. (2003). Therapiealternativen in der Immunsuppression — Mycophenolat-Mofetil und 6-Thioguanin. In: Dignass, A., Stein, J. (eds) Chronisch entzündliche Darmerkrankungen. Gastroenterologie Update, vol 2002. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19025-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-19025-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-44152-6
Online ISBN: 978-3-642-19025-4
eBook Packages: Springer Book Archive